HALMED participates in the WEB-RADR project
09.10.2014
The Agency for Medicinal Products and Medical Devices (HALMED) participates in the European Commission’s project Innovative Medicines Initiative WEB-RADR (Recognising Adverse Drug Reactions). It is a joint private public partnership project (IMI project) that aims at developing the easiest and most accessible reporting system for suspected adverse reactions to medicines by using new channels and social networks. In this project, in addition to HALMED, the European Medicines Agency (EMA) and the Medicines and Healthcare Regulatory Agency (MHRA) also actively participate in the project. HALMED has received compliments for its contribution by the American Food and Drug Administration (FDA) and Croatia will alongside the FDA voluntarily contribute to the project to facilitate the reporting of suspected adverse reactions by using mobile apps.
The WEB-RADR project is intended to develop new tools for data gathering on suspected adverse drug reactions, as well as to search for new technologies and platforms for safety monitoring of medicinal products in the European Union. The development of mobile apps for reporting suspected adverse drug reactions to competent authorities in the EU and tools for searching relevant data on social networks is foreseen by the project. A comprehensive scientific research will be carried out within the project based on which recommendations will be given about the future use of these tools in pharmacovigilance to protect the public health.
